Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus DEXASPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus DEXASPORIN.
CORTENEMA vs DEXASPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Category C
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination